Photo: ca.news.yahoo.com
"Eli Lilly Partners with Cipla for Tirzepatide Weight Loss Brand in India"
Eli Lilly and Company has partnered with Cipla to market the weight loss drug Tirzepatide in India, expanding access to obesity treatment options in the region.
- Eli Lilly and Company has signed an agreement with Cipla, allowing the Indian company to sell Tirzepatide under the brand name Yurpeak in India.
- Tirzepatide will be available in India as a once-weekly pre-filled injector pen, similar to the existing Mounjaro Kwikpen by Eli Lilly.
- The partnership aims to provide effective weight loss and diabetes management solutions for individuals suffering from obesity and type 2 diabetes in India.
Why It Matters
This collaboration between Eli Lilly and Company and Cipla is significant as it enhances access to innovative obesity treatments in India, a country facing rising diabetes and obesity rates. By making Tirzepatide more available, it could lead to improved health outcomes for many individuals.